Altimmune Inc (ALT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
37
About the Report
About the Report
Summary
Altimmune Inc (Altimmune), formerly Vaxin Inc is an immunotherapeutics company that develops vaccines and other biological products. The company's products include nasovax, an intranasally administered recombinant influenza vaccine; and heptcell, an immunotherapy for patients chronically infected with the hepatitis B virus. Its preclinical stage products include nasoshield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and oncosyn, an immunotherapeutic for treating solid cancer indications. Altimmune's products are used in the treatment of acute respiratory infections, chronic viral infections, and cancer. The company uses respirvec and densigen technologies for the development of vaccines. It has operations in London, UK; and Strasbourg, France. Altimmune is headquartered in Gaithersburg, Maryland, the US.
Altimmune Inc (ALT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Altimmune Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Altimmune Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Altimmune Inc, Medical Devices Deals, 2012 to YTD 2018 9
Altimmune Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Altimmune Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Vaxin Raises USD16 Million in Venture Financing 11
Partnerships 12
Altimmune Enters into Contract Agreement with BARDA for NasoShield 12
Merger 13
Altimmune Merges with PharmAthene in Reverse Merger Transaction 13
Licensing Agreements 15
Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 15
Equity Offering 16
Altimmune to Raise USD25 Million in Private Placement of Units 16
Altimmune Raises USD12 Million in Public Offering of Shares 17
Altimmune Raises USD4.9 Million in Private Placement of Shares 19
Altimmune Raises USD14.7 Million in Private Placement of Series B Preferred Shares 20
Asset Transactions 22
WCCT Acquires Challenge Virus from Immune Targeting Systems 22
Acquisition 23
Vaxin Acquires Immune Targeting Systems 23
Altimmune Inc-Key Competitors 24
Altimmune Inc-Key Employees 25
Altimmune Inc-Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Aug 14, 2018: Altimmune announces second quarter 2018 financial results and provides corporate update 27
May 15, 2018: Altimmune Reports First Quarter 2018 Financial Results 28
Mar 28, 2018: Altimmune Reports Financial Results for the Year Ended December 31, 2017 29
Nov 09, 2017: Altimmune Announces Third Quarter 2017 Financial Results and Provides Corporate Update 31
Aug 10, 2017: Altimmune Announces Second Quarter 2017 Financial Results and Provides Corporate Update 33
Corporate Communications 34
Jul 10, 2018: Altimmune Appoints Mitchel Sayare as Executive Chairman of the Board, and Adds Jose Ochoa to Its Leadership Team as Chief Business Officer 34
Jan 03, 2018: Altimmune Elects Mitchel Sayare, Ph.D. as Chairman of its Board of Directors 35
May 16, 2017: Altimmune Promotes Dr. Sybil Tasker to Chief Medical Officer 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37
List of Figure
List of Figures
Altimmune Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Altimmune Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Altimmune Inc, Medical Devices Deals, 2012 to YTD 2018 9
List of Table
List of Tables
Altimmune Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Altimmune Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Altimmune Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Altimmune Inc, Medical Devices Deals, 2012 to YTD 2018 9
Altimmune Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Vaxin Raises USD16 Million in Venture Financing 11
Altimmune Enters into Contract Agreement with BARDA for NasoShield 12
Altimmune Merges with PharmAthene in Reverse Merger Transaction 13
Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 15
Altimmune to Raise USD25 Million in Private Placement of Units 16
Altimmune Raises USD12 Million in Public Offering of Shares 17
Altimmune Raises USD4.9 Million in Private Placement of Shares 19
Altimmune Raises USD14.7 Million in Private Placement of Series B Preferred Shares 20
WCCT Acquires Challenge Virus from Immune Targeting Systems 22
Vaxin Acquires Immune Targeting Systems 23
Altimmune Inc, Key Competitors 24
Altimmune Inc, Key Employees 25
Altimmune Inc, Subsidiaries 26
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.